Form 4/A for NVCR NovoCure Ltd
Accepted 2022-09-13 00:00:00 ET · period of report 2022-09-08 · accession 0001645113-22-000081 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-09-13 | 2022-09-08 | NVCR | Leonard Frank X | Chief Development Off | S - Sale | $81.48 | -6,754 | 77.4K | -8% | -$550.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-09-08 | S | D | 6,754 | $81.48 | 77,396 | D | — | — | (F1) Amending original Form 4 filed on September 12, 2022 to add additional transaction inadvertently omitted. (F2) Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Mr. Leonard. |